IK Investment Partners’ IK VIII Fund is to acquire ZytoService Group, a compounder of pharmaceuticals for patient-individualised infusions, from the founders and Capiton.
Financial terms of the transaction have not been disclosed.
Founded in 2002, ZytoService is based in Hamburg, where it runs a compounding facility.
“We are delighted to be working with IK going forward. ZytoService operates in an industry in which IK has extensive expertise, and with their support we will be well placed to further expand our competence and provide the best service to our customers,” says Enno Scheel, co-founder of ZytoService.
“We firmly believe in the strengths of partnering with IK. Together, we will continue investing in the business to better address the growing demands of the German healthcare market,” adds Thomas Boner, co-founder of ZytoService.
Scheel and Boner will remain with the business in managerial roles, and will be shareholders alongside IK.
“Thanks to IK’s experience in the relevant sector, we quickly recognised ZytoService’s potential. We look forward to backing the management team and expanding the company’s operational capabilities. We believe ZytoService is ideally positioned to develop further and provide highest quality services to its customers,” says Detlef Dinsel, managing partner at IK and adviser to the IK VIII Fund.
Completion of the transaction is subject to custom legal and regulatory approvals.
ZytoService will be the second investment of the 2016 established IK VIII Fund.
